Amgen Hiding Biosimilar Info, Genentech Suit Says
Amgen is hypocritically withholding information about its proposed biosimilar of cancer drug Avastin and thereby undercutting potential patent litigation, Genentech charged in a complaint filed Wednesday in Delaware federal court....To view the full article, register now.
Already a subscriber? Click here to view full article